Mapping of prostate cancer by 1H MRSI

NMR in Biomedicine

Volumn 27, Issue 1, 2014, Pages 39-52

  Kobus, Thiele ^a   Wright, Alan J ^a   Scheenen, Tom W J ^a   Heerschap, Arend ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer biomarkers; Clinical applications; Data acquisition; MRS; Post processing; Prostate cancer; Prostate MRSI; Review

Indexed keywords

CANCER BIOMARKERS; CLINICAL APPLICATION; MRS; POST PROCESSING; PROSTATE CANCERS; PROSTATE MRSI;

DATA ACQUISITION; DATA HANDLING; REVIEWS; THREE DIMENSIONAL; UROLOGY;

DISEASES;

BIOLOGICAL MARKER; TUMOR MARKER;

AGGRESSIVENESS; ARTICLE; CANCER LOCALIZATION; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPUTER; COMPUTER PROGRAM; DIAGNOSTIC IMAGING; DISEASE SURVEILLANCE; FOURIER TRANSFORMATION; HUMAN; IMAGE DISPLAY; NUCLEAR MAGNETIC RESONANCE SCANNER; PATTERN RECOGNITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; THREE DIMENSIONAL IMAGING;

CANCER BIOMARKERS; CLINICAL APPLICATIONS; DATA ACQUISITION; MRS; POST-PROCESSING; PROSTATE CANCER; PROSTATE MRSI; REVIEW;

HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATIC NEOPLASMS; PROTONS;

EID: 84890875538     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2973     Document Type: Article

References (140)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012; 62(1): 10-29.
2. Hoeks CMA, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SWT, Scheenen TWJ, Vos PC, Huisman H, Van Oort IM, Witjes JA, Heerschap A, Futterer J. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261(1): 46-66.
3. 31P magnetic resonance spectroscopy. J. Urol. 1993; 150(6): 2019-2024.
4. 1H magnetic resonance spectroscopy and biochemical study. Magn. Reson. Med. 1993; 29(2): 149-157.
5. Heerschap A, Jager GJ, Van Der Graaf M, Barentsz JO, Ruijs SHJ. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn. Reson. Med. 1997; 37(2): 204-213.
6. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995; 45(3): 459-466.
7. Heerschap A, Jager GJ, Van Der Graaf M, Barentsz JO, De La Rosette JJM, Oosterhof GON, Ruijter ETG, Ruijs SHJ. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997; 17(3A): 1455-1460.
8. 3) spatial resolution. Radiology 1996; 198(3): 795-805.
9. Van Der Graaf M, Van Den Boogert HJ, Jager GJ, Barentsz JO, Heerschap A. Human prostate: multisection proton MR spectroscopic imaging with a single spin-echo sequence - preliminary experience. Radiology 1999; 213(3): 919-925.
10. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn. Reson. Med. 2004; 52(1): 80-88.
11. Kim Y, Hsu ICJ, Pouliot J, Noworolski SM, Vigneron DB, Kurhanewicz J. Expandable and rigid endorectal coils for prostate MRI: impact on prostate distortion and rigid image registration. Med. Phys. 2005; 32(12): 3569-3578.
12. Noworolski SM, Crane JC, Vigneron DB, Kurhanewicz J. A clinical comparison of rigid and inflatable endorectal-coil probes for MRI and 3D MR spectroscopic imaging (MRSI) of the prostate. J. Magn. Reson. Imaging 2008; 27(5): 1077-1082.
13. Noworolski SM, Reed GD, Kurhanewicz J, Vigneron DB. Post-processing correction of the endorectal coil reception effects in MR spectroscopic imaging of the prostate. J. Magn. Reson. Imaging 2010; 32(3): 654-662.
14. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ. ESUR prostate MR guidelines 2012. Eur. Radiol. 2012; 22(4): 746-757.
15. Kaji Y, Wada A, Imaoka I, Matsuo M, Terachi T, Kobashi Y, Sugimura K, Fujii M, Maruyama K, Takizawa O. Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil. J. Magn. Reson. Imaging 2002; 16(6): 697-706.
16. Lichy MP, Pintaske J, Kottke R, Machann J, Anastasiadis A, Roell S, Hennenlotter J, Diergarten T, Schick F, Stenzl A, Claussen CD, Schlemmer HP. 3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5T in clinical routine: a feasibility study. Eur. Radiol. 2005; 15(4): 653-660.
17. 1H-spectroscopic imaging of the prostate. Invest. Radiol. 2004; 39(11): 671-680.
18. Chen AP, Cunningham CH, Kurhanewicz J, Xu D, Hurd RE, Pauly JM, Carvajal L, Karpodinis K, Vigneron DB. High-resolution 3D MR spectroscopic imaging of the prostate at 3T with the MLEV-PRESS sequence. Magn. Reson. Imaging 2006; 24(7): 825-832.
19. 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 tesla: should we use an endorectal coil? Invest. Radiol. 2011; 46(5): 301-306.
20. 1H MR spectroscopy of normal and malignant human prostates in vivo. J. Magn. Reson. B 1990; 87(3): 610-619.
21. Schick F, Bongers H, Kurz S, Jung WI, Pfeffer M, Lutz O. Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5T. Magn. Reson. Med. 1993; 29(1): 38-43.
22. Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J. Natl. Cancer Inst. Monogr. 2012; 2012(45): 146-151.
23. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB. Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn. Reson. Med. 2001; 46(6): 1079-1087.
24. Cunningham CH, Vigneron DB, Chen AP, Xu D, Hurd RE, Sailasuta N, Pauly JM. Design of symmetric-sweep spectral-spatial RF pulses for spectral editing. Magn. Reson. Med. 2004; 52(1): 147-153.
25. Males RG, Vigneron DB, Star Lack O, Falbo SC, Nelson SJ, Hricak H, Kurhanewicz J. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D H-1 magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2000; 43(1): 17-22.
26. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn. Reson. Med. 1997; 38(2): 311-321.
27. Mescher M, Tannus A, Johnson MO, Garwood M. Solvent suppression using selective echo dephasing. J. Magn. Reson. A 1996; 123(2): 226-229.
28. Tran TKC, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson S, Hurd R. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn. Reson. Med. 2000; 43(1): 23-33.
29. 1H-MRSI. Magn. Reson. Imaging 2012; 30(2): 195-204.
30. 1H-MRSI of the prostate. NMR Biomed. 2012; 25(4): 643-653.
31. Mareci TH, Brooker HR. Essential considerations for spectral localization using indirect gradient encoding of spatial information. J. Magn. Reson. 1991; 92(2): 229-246.
32. Pohmann R, von Kienlin M. Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI. Magn. Reson. Med. 2001; 45(5): 817-826.
33. Near J, Romagnoli C, Curtis AT, Klassen LM, Izawa J, Chin J, Bartha R. High-field MRSI of the prostate using a transmit/receive endorectal coil and gradient modulated adiabatic localization. J. Magn. Reson. Imaging 2009; 30(2): 335-343.
34. 1H MR spectroscopic imaging of aggressive prostate cancer: can we detect lactate? Magn. Reson. Med. 2013; DOI: 10.1002/mrm.24635.
35. Katscher U, Börnert P, Leussler C, Van den Brink JS. Transmit SEN. Magn. Reson. Med. 2003; 49(1): 144-150.
36. Zhu Y. Parallel excitation with an array of transmit coils. Magn. Reson. Med. 2004; 51(4): 775-784.
37. Thiel T, Czisch M, Elbel GK, Hennig J. Phase coherent averaging in magnetic resonance spectroscopy using interleaved navigator scans: compensation of motion artifacts and magnetic field instabilities. Magn. Reson. Med. 2002; 47(6): 1077-1082.
38. Kim DH, Adalsteinsson E, Spielman DM. Spiral readout gradients for the reduction of motion artifacts in chemical shift imaging. Magn. Reson. Med. 2004; 51(3): 458-463.
39. Chen AP, Cunningham CH, Ozturk-Isik E, Xu D, Hurd RE, Kelley DAC, Pauly JM, Kurhanewicz J, Nelson SJ, Vigneron DB. High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J. Magn. Reson. Imaging 2007; 25(6): 1288-1292.
40. 1H MR metabolic imaging in the clinic. Radiology 2012; 262(3): 985-994.
41. Van der Graaf M, Heerschap A. Effect of cation binding on the proton chemical shifts and the spin-spin coupling constant of citrate. J. Magn. Reson. B 1996; 112(1): 58-62.
42. Moore GJ, Sillerud LO. The pH dependence of chemical shift and spin-spin coupling for citrate. J. Magn. Reson. B 1994; 103(1): 87-88.
43. Van der Graaf M, Jager GJ, Heerschap A. Removal of the outer lines of the citrate multiplet in proton magnetic resonance spectra of the prostatic gland by accurate timing of a point-resolved spectroscopy pulse sequence. Magn. Reson. Mater. Phys. 1997; 5(1): 65-69.
44. Scheenen TWJ, Fütterer J, Weiland E, Van Hecke P, Lemort M, Zechmann C, Schlemmer HP, Broome D, Villeirs G, Lu J, Barentsz J, Roell S, Heerschap A. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest. Radiol. 2011; 46(1): 25-33.
45. Trabesinger AH, Meier D, Dydak U, Lamerichs R, Boesiger P. Optimizing PRESS localized citrate detection at 3 Tesla. Magn. Reson. Med. 2005; 54(1): 51-58.
46. Mulkern RV, Bowers JL, Peled S, Williamson DS. Density-matrix calculations of the 1.5T citrate signal acquired with volume-localized STEAM sequences. J. Magn. Reson. B 1996; 110(3): 255-266.
47. 1H MRS localization sequences. J. Magn. Reson. B 1995; 107(1): 25-33.
48. 1H-MR spectroscopic imaging of the human prostate at 3T. Magn. Reson. Med. 2005; 53(6): 1268-1274.
49. Verma S, Rajesh A, Fütterer JJ, Turkbey B, Scheenen TWJ, Pang Y, Choyke PL, Kurhanewicz J. Prostate MRI and 3D MR spectroscopy: how we do it. Am. J. Roentgenol. 2010; 194(6): 1414-1426.
50. Van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. Magma (New York, NY) 2000; 10(3): 153-159.
51. Spencer NG, Eykyn TR, DeSouza NM, Payne GS. The effect of experimental conditions on the detection of spermine in cell extracts and tissues. NMR Biomed. 2010; 23(2): 163-169.
52. Klomp DWJ, Scheenen TWJ, Arteaga CS, van Asten J, Boer VO, Luijten PR. Detection of fully refocused polyamine spins in prostate cancer at 7T. NMR Biomed. 2011; 24(3): 299-306.
53. Dunzendorfer U, Russell DH. Altered polyamine profiles in prostatic hyperplasia and in kidney tumors. Cancer Res. 1978; 38(8): 2321-2324.
54. Lowry M, Liney GP, Turnbull LW, Manton DJ, Blackband SJ, Horsman A. Quantification of citrate concentration in the prostate by proton magnetic resonance spectroscopy: zonal and age-related differences. Magn. Reson. Med. 1996; 36(3): 352-358.
55. 1H MRS of Prostate Pathology. Proceedings of the 3rd Annual Meeting of ISMRM, New York, New York, USA, 1995; 1: 213.
56. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991; 18(1): 25-46.
57. Costello LC, Franklin RB. Citrate metabolism of normal and malignant prostate epithelial cells. Urology 1997; 50(1): 3-12.
58. Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998; 35(4): 285-296.
59. Kavanagh JP. Sodium, potassium, calcium, magnesium, zinc, citrate and chloride content of human prostatic and seminal fluid. J. Reprod. Fertil. 1985; 75(1): 35-41.
60. Langer DL, Van Der Kwast TH, Evans AJ, Plotkin A, Trachtenberg J, Wilson BC, Haider MA. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, Ktrans, Ve, and corresponding histologic features. Radiology 2010; 255(2): 485-494.
61. 1H MRS and MRI. Magn. Reson. Imaging 1997; 15(10): 1177-1186.
62. 1H HR-MAS spectroscopy. Magn. Reson. Med. 2006; 55(6): 1257-1264.
63. Cohen RJ, Fujiwara K, Holland JW, McNeal JE. Polyamines in prostatic epithelial cells and adenocarcinoma; the effects of androgen blockade. Prostate 2001; 49(4): 278-284.
64. Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease. Prostate 1997; 30(4): 248-255.
65. Cheng LL, Wu CL, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS H-1 NMR spectroscopy at 9.4T. FEBS Lett. 2001; 494(1-2): 112-116.
66. Lynch MJ, Masters J, Pryor JP, Lindon JC, Spraul M, Foxall PJ, Nicholson JK. Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. J. Pharm. Biomed. Anal. 1994; 12(1): 5-19.
67. Kassen A, Sutkowski DM, Ahn H, Sensibar JA, Kozlowski JM, Lee C. Stromal cells of the human prostate: initial isolation and characterization. Prostate 1998; 28(2): 89-97.
68. Cooper JF, Farid I. Role of citric acid in physiology of prostate. 3. Lactate/citrate ratios in benign and malignant prostatic homogenates as index of prostatic malignancy. J. Urol. 1964; 92(5): 533-536.
69. Bertilsson H, Tessem MB, Flatberg A, Viset T, Gribbestad I, Angelsen A, Halgunset J. Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples. Clin. Cancer Res. 2012; 18(12): 3261-3269.
70. Hom JJ, Coakley FV, Simko JP, Lu Y, Qayyum A, Westphalen ACA, Schmitt LD, Carroll PR, Kurhanewicz J. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features - initial experience. Radiology 2007; 242(2): 483-489.
71. Van Asten JJA, Cuijpers V, Hulsbergen-Van De Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. Magn. Reson. Mater. Phys. 2008; 21(6): 435-442.
72. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005; 65(8): 3030-3034.
73. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med. 2003; 50(5): 944-954.
74. Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007; 245(2): 499-506.
75. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61(9): 3599-3603.
76. 1H HR-MAS total correlation spectroscopy. Magn. Reson. Med. 2008; 60(1): 33-40.
77. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat. Rev. Cancer 2011; 11(12): 835-848.
78. Dorsten F, Engelbrecht M, Van der Graaf M, De La Rosette J, Barentsz JO, Heerschap A. Differentiation of Prostatitis from Prostate Carcinoma using 1H MR Spectroscopic Imaging and Dynamic Contrast-Enhanced MRI. Proceedings of the 9th Annual Meeting of ISMRM, Glasgow, Scotland, UK, 2001; 632.
79. 1H MR spectroscopic imaging findings - initial observations. Radiology 2004; 231(3): 717-724.
80. Testa C, Schiavina R, Lodi R, Salizzoni E, Tonon C, D'Errico A, Corti B, Morselli-Labate AM, Franceschelli A, Bertaccini A. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed. 2010; 23(9): 1017-1026.
81. Nagel KN, Schouten MG, Hambrock T, Litjens GJ, Hoeks CM, ten Haken B, Barentsz JO, Fütterer JJ. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3T. Radiology 2013; 267: 164-172.
82. Tomlins AM, Foxall PJD, Lynch MJ, Parkinson J, Everett JR, Nicholson JK. High resolution (1)H NMR spectroscopic studies on dynamic biochemical processes in incubated human seminal fluid samples. BBA Gen. Subjects 1998; 1379(3): 367-380.
83. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, Carroll PR, Kurhanewicz J. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. Am. J. Roentgenol. 2004; 183(4): 1079-1083.
84. Barrett T, Vargas HA, Akin O, Goldman DA, Hricak H. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology 2012; 263(3): 751-757.
85. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236(3): 903-910.
86. Kobus T, Hambrock T, Hulsbergen-Van De Kaa CA, Wright AJ, Barentsz JO, Heerschap A, Scheenen TWJ. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3T with an endorectal coil. Eur. Urol. 2011; 60(5): 1074-1080.
87. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234(3): 804-814.
88. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233(3): 701-708.
89. Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotto CK, Cho H, Kawashima A, Tempany-Afdhal CM, Macura KJ, Rosen M, Gerst SR, Kurhanewicz J. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy - results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251(1): 122-133.
90. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology 2007; 245(2): 507-516.
91. Schipper RG, Romijn JC, Cuijpers VMJI, Verhofstad AAJ. Polyamines and prostatic cancer. Biochem. Soc. Trans. 2003; 31(2): 375-380.
92. 1H-MRSI in vivo at 3 Tesla. Magn. Reson. Med. 2011; 65(4): 914-919.
93. Pels P, Osturk-Isik E, Swanson MG, Vanhamme L, Kurhanewicz J, Nelson SJ, Van Huffel S. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed. 2006; 19(2): 188-197.
94. Van Dorsten FA, Van der Graaf M, Engelbrecht MR, Van Leenders GJ, Verhofstad A, Rijpkema M, De la Rosette JJ, Barentsz JO, Heerschap A. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J. Magn. Reson. Imaging 2004; 20(2): 279-287.
95. Kobus T, Vos PC, Hambrock T, De Rooij M, Hulsbergen-Van De Kaa CA, Barentsz JO, Heerschap A, Scheenen TWJ. Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3T. Radiology 2012; 265(2): 457-467.
96. Crehange G, Maingon P, Gauthier M, Parfait S, Cochet A, Mirjolet C, Bonnetain F, Cormier L, Brunotte F, Walker P. Early choline levels from 3-Tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1year. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81(4): e407-e413.
97. 1H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings. Magn. Res. Med. 2011; 65(2): 329-339.
98. Poullet JB, Sima DM, Van Huffel S. MRS signal quantitation: a review of time- and frequency-domain methods. J. Magn. Reson. 2008; 195(2): 134-144.
99. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30(6): 672-679.
100. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 1997; 129(1): 35-43.
101. Ratiney H, Sdika M, Coenradie Y, Cavassila S, Ormondt DV, Graveron-Demilly D. Time-domain semi-parametric estimation based on a metabolite basis set. NMR Biomed. 2005; 18(1): 1-13.
102. Poullet JB, Sima DM, Simonetti AW, De Neuter B, Vanhamme L, Lemmerling P, Van Huffel S. An automated quantitation of short echo time MRS spectra in an open source software environment: AQSES. NMR Biomed. 2007; 20(5): 493-504.
103. Reynolds G, Wilson M, Peet A, Arvanitis TN. An algorithm for the automated quantitation of metabolites in in vitro NMR signals. Magn. Reson. Med. 2006; 56(6): 1211-1219.
104. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999; 213(2): 473-480.
105. Nelson SJ, Brown TR. The accuracy of quantification from 1D NMR spectra using the PIQABLE algorithm. J. Magn. Reson. 1989; 84(1): 95-109.
106. 1H MRSI data of the prostate. NMR Biomed. 2012; 25(5): 755-765.
107. 1H MRSI data of the prostate. Magn. Reson. Med. 2012; 68: 1724-1730.
108. Brown TR, Stoyanova R. NMR spectral quantitation by principal-component analysis. II. Determination of frequency and phase shifts. J. Magn. Reson. B 1996; 112(1): 32-43.
109. Witjes H, Melssen WJ, in't Zandt HJ, van der Graaf M, Heerschap A, Buydens LM. Automatic correction for phase shifts, frequency shifts, and lineshape distortions across a series of single resonance lines in large spectral data sets. J. Magn. Reson. 2000; 144(1): 35-44.
110. Nelson SJ, Brown TR. A method for automatic quantification of one-dimensional spectra with low signal-to-noise ratio. J. Magn. Reson. 1987; 75(2): 229-243.
111. 1H mrsi data of patients with prostate cancer. Acad. Radiol. 2012; 19(6): 675-684.
112. Fütterer JJ, Scheenen TWJ, Heijmink SWT, Huisman HJ, Hulsbergen-Van De Kaa CA, Witjes JA, Heerschap A, Barentsz JO. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest. Radiol. 2007; 42(2): 116-122.
113. 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur. Radiol. 2005; 15(4): 645-652.
114. 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology 2008; 246(2): 480-488.
115. 1H MRSI data. NMR Biomed. 2013; 26: 193-203.
116. Kelm BM, Menze BH, Zechmann CM, Baudendistel KT, Hamprecht FA. Automated estimation of tumor probability in prostate magnetic resonance spectroscopic imaging: pattern recognition vs quantification. Magn. Reson. Med. 2007; 57(1): 150-159.
117. Tiwari P, Rosen M, Madabhushi A. A hierarchical spectral clustering and nonlinear dimensionality reduction scheme for detection of prostate cancer from magnetic resonance spectroscopy (MRS). Med. Phys. 2009; 36(9): 3927.
118. Laudadio T, Pels P, De Lathauwer L, Van Hecke P, Van Huffel S. Tissue segmentation and classification of MRSI data using canonical correlation analysis. Magn. Reson. Med. 2005; 54(6): 1519-1529.
119. Croitor Sava AR, Sima DM, Poullet J-B, Wright AJ, Heerschap A, Van Huffel S. Exploiting spatial information to estimate metabolite levels in two-dimensional MRSI of heterogeneous brain lesions. NMR Biomed. 2011; 24(7): 824-835.
120. Fütterer JJ, Heijmink SWT, Scheenen TWJ, Veltman J, Huisman HJ, Vos P, Hulsbergen-Van De Kaa CA, Witjes JA, Krabbe PFM, Heerschap A, Barentsz JO. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241(2): 449-458.
121. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur. J. Radiol. 2011; 77(2): 340-345.
122. Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, Lau WK, Ng WS, Cheng CW. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J. Urol. 2004; 171(4): 1482-1486.
123. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Bernardo S, Passariello R. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin. Cancer Res. 2010; 16(6): 1875-1883.
124. 1H MR spectroscopic imaging to segregate patients who are likely to show malignancy of the peripheral zone of the prostate on biopsy. J. Magn. Reson. Imaging 2009; 30(4): 842-848.
125. Selnæs KM, Heerschap A, Jensen LR, Tessem M-B, Jarosch-Von Schweder G, Goa PE, Viset T, Angelsen A, Gribbestad IS. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3T: unbiased cancer identification by matching to histopathology. Invest. Radiol. 2012; 47(11): 624-633.
126. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213(2): 481-488.
127. Futterer JJ, Heijmink SW, Scheenen TW, Jager GJ, Hulsbergen-Van de Kaa CA, Witjes JA, Barentsz JO. Prostate cancer: local staging at 3-T endorectal MR imaging - early experience. Radiology 2006; 238(1): 184-191.
128. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging 2002; 16(4): 451-463.
129. Shukla-Dave A, Hricak H, Ishill NM, Moskowitz CS, Drobnjak M, Reuter VE, Zakian KL, Scardino PT, Cordon-Cardo C. Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, Phospho-Akt, and androgen receptor expression in prostate cancer. Radiology 2009; 250(3): 803-812.
130. Kurhanewicz J, Vigneron DB, Hricak H, Parivar F, Nelson SJ, Shinohara K, Carroll PR. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996; 200(2): 489-496.
131. Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, Carroll PR. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996; 48(4): 594-599.
132. Coakley FV, Hui ST, Qayyum A, Swanson MG, Lu Y, Roach Iii M, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004; 233(2): 441-448.
133. Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004; 60(4): 1047-1055.
134. Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, Ebora LE, Scardino PT, Koutcher JA, Zakian KL. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy - initial experience. Radiology 2005; 236(2): 545-553.
135. Zaider M, Zelefsky MJ, Lee EK, Zakian KL, Amols HI, Dyke J, Cohen G, Hu YC, Endi AK, Chui CS, Koutcher JA. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47(4): 1085-1096.
136. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, Wood PJ, Noworolski S, Nelson SJ, Barken I, Carroll PR, Kurhanewicz J. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2001; 46(1): 49-57.
137. Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010; 256(1): 176-183.
138. Cabrera AR, Coakley FV, Westphalen AC, Lu Y, Zhao S, Shinohara K, Carroll PR, Kurhanewicz J. Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? Radiology 2008; 247(2): 444-450.
139. 1H MR spectroscopic imaging of the prostate at 1.5T. J. Magn. Reson. Imaging 2012; 35(1): 166-173.
140. Shukla-Dave A, Hricak H, Akin O, Yu C, Zakian KL, Udo K, Scardino PT, Eastham J, Kattan MW. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int. 2012; 109(9): 1315-1322.